Keros Therapeutics (NASDAQ:KROS) Announces Earnings Results, Beats Estimates By $1.66 EPS

Keros Therapeutics (NASDAQ:KROS) released its quarterly earnings results on Thursday. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of ($0.96) by $1.66, FiscalAI reports. The business had revenue of $40.01 million for the quarter, compared to analyst estimates of $14.76 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%.

Keros Therapeutics Price Performance

Shares of KROS stock traded down $0.09 on Friday, hitting $9.36. 192,038 shares of the company’s stock were exchanged, compared to its average volume of 297,118. Keros Therapeutics has a 12 month low of $9.26 and a 12 month high of $22.55. The stock has a market cap of $185.61 million, a P/E ratio of -2.53 and a beta of 1.13. The company has a 50 day moving average of $11.22 and a 200 day moving average of $11.97.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on KROS shares. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Keros Therapeutics in a report on Tuesday, August 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Zacks Research raised shares of Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 27th. Leerink Partners reduced their price objective on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 4th. Finally, Wall Street Zen downgraded shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, November 1st. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Keros Therapeutics has a consensus rating of “Hold” and a consensus target price of $21.40.

Keros Therapeutics declared that its board has approved a share repurchase program on Wednesday, September 9th that allows the company to repurchase $5 million in outstanding shares. This buyback authorization allows the company to repurchase up to 2.3% of its stock through open market purchases. Share buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Insider Transactions at Keros Therapeutics

In other Keros Therapeutics news, insider Lorena Raquel Lerner sold 3,568 shares of Keros Therapeutics stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $36,714.72. Following the transaction, the insider owned 27,559 shares in the company, valued at $283,582.11. The trade was a 11.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 5,343 shares of company stock valued at $54,985 in the last quarter. Insiders own 12.60% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.